SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

Kim, Eunhee, Ilagan, Janine O., Liang, Yang, Daubner, Gerrit M., Lee, Stanley C.-W., Ramakrishnan, Aravind, Li, Yue, Chung, Young Rock +17 more·2015·Cancer Cell
DOI 10.1016/j.ccell.2015.04.006

Cited by (582)

Items 201–300 of 582

  1. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms
    Gabriele Todisco, Maria Creignou, Anna Gallì, Paola Guglielmelli, Elisa Rumi, Marco Roncador, Ettore Rizzo, Yasuhito Nannya, Daniela Pietra, Chiara Elena et al. · 2020 · Leukemia
  2. Aberrant RNA splicing and therapeutic opportunities in cancers
    Hirofumi Yamauchi, Kazuki Nishimura, Akihide Yoshimi · 2021 · Cancer Science
  3. Genome-guided discovery of cancer therapeutic targets
    Prathyusha Konda, Simon Garinet, Eliezer M. Van Allen, Srinivas Raghavan Viswanathan · 2023 · Cell Reports
  4. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications
    Andrea Pellagatti, Jacqueline Boultwood · 2016 · Advances in Biological Regulation
  5. How do messenger RNA splicing alterations drive myelodysplasia?
    Poorval M. Joshi, Stephanie Halene, Omar Ibrahim Abdel-Wahab · 2017 · Blood
  6. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1
    Shuiling Jin, Hairui Su, Ngoc Tung Tran, Jing Song, Sydney X. Lu, Ying Li, Suming Huang, Omar Ibrahim Abdel-Wahab, Yanyan Liu, Xinyang Zhao · 2017 · PLoS ONE
  7. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
    Yang, Yi-Tsung, Chiu, Yu-Chiao, Kao, Chein-Jun, Hou, Hsin-An, Lin, Chien-Chin, Tsai, Cheng-Hong, Tseng, Mei-Hsuan, Chou, Wen-Chien, Tien, Hwei-Fang · 2018 · Blood Cancer Journal
  8. Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice
    Chang Zhang, Lei Shen, Wei Yuan, Yuguo Liu, Ruochen Guo, Yangjun Luo, Zheng Zhan, Zhiqin Xie, Guohao Wu, Wenwu Wu et al. · 2020 · Communications Biology
  9. Role of reactive oxygen species in myelodysplastic syndromes
    Qiangan Jing, Chaoting Zhou, Junyu Zhang, Ping Zhang, Yunyi Wu, Junyu Zhou, Xiangmin Tong, Yanchun Li, Jing Du, Ying Wang · 2024 · Cellular & Molecular Biology Letters
  10. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
    Marcus Bauer, Christoforos Vaxevanis, Nadine Heimer, Haifa Kathrin Al‐Ali, Nadja Jaekel, Michael Philipp Bachmann, Claudia Wickenhauser, Barbara Seliger · 2020 · International Journal of Molecular Sciences
  11. RNA-binding proteins of COSMIC importance in cancer
    Peter S. Choi, Andrei Thomas‐Tikhonenko · 2021 · Journal of Clinical Investigation
  12. MEN1 is a regulator of alternative splicing and prevents R-loop-induced genome instability through suppression of RNA polymerase II elongation
    Bangming Jin, Jiamei Zhu, Ting Shuang Pan, Yunqiao Yang, Li Liang, Yüxia Zhou, Tuo Zhang, Yin Teng, Ziming Wang, Xuyan Wang et al. · 2023 · Nucleic Acids Research
  13. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Phaedon D. Zavras, Ilias Sinanidis, Panagiotis Tsakiroglou, Theodoros Karantanos · 2023 · International Journal of Molecular Sciences
  14. Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities
    Daichi Inoue, Omar Ibrahim Abdel-Wahab · 2016 · Cancer Cell
  15. ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching
    Paolo Cifani, Avantika Dhabaria, Zining Chen, Akihide Yoshimi, Emily A. Kawaler, Omar Ibrahim Abdel-Wahab, John Thomas Poirier, Alex Kentsis · 2018 · Journal of Proteome Research
  16. Myeloid Disease Mutations of Splicing Factor SRSF2 Cause G2-M Arrest and Skewed Differentiation of Human Hematopoietic Stem and Progenitor Cells
    Aditi Bapat, Nakia Keita, William Martelly, Paul T Kang, Christopher S. Seet, Jeffery R. Jacobsen, Peter Stoilov, Chengcheng Hu, Gay M. Crooks, Shalini Sharma · 2018 · Stem Cells
  17. Alternative RNA splicing in tumour heterogeneity, plasticity and therapy
    Sebastian Pohl, Kevin Myant · 2022 · Disease Models & Mechanisms
  18. METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
    Yiming Wu, Meiling Jin, Mike Minh Fernandez, Kevyn L. Hart, Aijun Liao, Xinzhou Ge, Stacey M. Fernandes, Tinisha McDonald, Zhenhua Chen, Daniel Röth et al. · 2023 · Blood Cancer Discovery
  19. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome
    Feng Xu, Li Liu, Chunkang Chang, Qi He, Lingyun Wu, Zheng Zhang, Wen-Hui Shi, Juan Guo, Yang Zhu, Youshan Zhao et al. · 2016 · Oncotarget
  20. snRNP proteins in health and disease
    Michaela Krausová, David Staněk · 2017 · Seminars in Cell and Developmental Biology
  21. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
    Michael Schieber, Christian Marinaccio, Lyndsey C. Bolanos, Wendy D. Haffey, Kenneth D. Greis, Daniel T. Starczynowski, John D. Crispino · 2020 · Blood Cancer Journal
  22. Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis
    Matthew A. McLoughlin, Sruthi Cheloor Kovilakam, William G. Dunn, Muxin Gu, Jake Tobin, Yash Pershad, Nicholas Williams, Daniel A. Leongamornlert, Kevin J. Dawson, Laura Bond et al. · 2025 · Nature Genetics
  23. Splicing factor mutant myelodysplastic syndromes: Recent advances
    Andrea Pellagatti, Jacqueline Boultwood · 2019 · Advances in Biological Regulation
  24. Tissue-specific regulation of gene expression via unproductive splicing
    Alexei Mironov, Marina V. Petrova, Sergey Margasyuk, Maria Vlasenok, Andrey A. Mironov, Dmitry Aleksandrovich Skvortsov, Dmitri Davidovich Pervouchine · 2023 · Nucleic Acids Research
  25. Therapeutic Targeting of RNA Splicing in Cancer
    Elizabeth A. Bonner, Stanley Chun-Wei Lee · 2023 · Genes
  26. Splicing regulatory factors in breast cancer hallmarks and disease progression
    Esmee Koedoot, Liesanne Wolters, Bob van de Water, Sylvia E. Le Dévédec · 2019 · Oncotarget
  27. Targeting RNA-binding proteins in acute and chronic leukemia
    Irina A. Elcheva, Vladimir S. Spiegelman · 2020 · Leukemia
  28. SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation
    Martina Cusan, Haifeng Shen, Bo Zhang, Aijun Liao, Lu Yang, Meiling Jin, Mike Minh Fernandez, Prajish Sundaram Iyer, Yiming Wu, Kevyn L. Hart et al. · 2023 · Journal of Clinical Investigation
  29. Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms
    Hiroko Sakurai, Yuka Harada, Yosuke Ogata, Yuki Kagiyama, Naoki Shingai, Noriko Doki, Kazuteru Ohashi, Toshio Kitamura, Norio Komatsu, Hironori Harada · 2017 · Blood Advances
  30. The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations
    Pushkar Malakar, Sudhanshu Kumar Shukla, Meghna Mondal, Rajesh Kumar Kar, Jawed Akhtar Siddiqui · 2023 · RNA Biology
  31. NUP98-HBO1–fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis
    Yoshihiro Hayashi, Yuka Harada, Yuki Kagiyama, Sayuri Nishikawa, Ye Ding, Jun Imagawa, Naoki Shingai, Naoko Kato, Jiro Kitaura, Shintaro Hokaiwado et al. · 2019 · Blood Advances
  32. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis
    Xue Yan Zheng, Zhi Zhan, Duolan Naren, Jing Li, Tianyou Yan, Yuping Gong · 2017 · PLoS ONE
  33. Clonal evolution and hierarchy in myeloid malignancies
    Koichi Takahashi, Tomoyuki N. Tanaka · 2023 · Trends in cancer
  34. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
    Richard Neil Armstrong, Violetta Steeples, Shalini Singh, Andrea Sanchi, Jacqueline Boultwood, Andrea Pellagatti · 2017 · Advances in Biological Regulation
  35. An Intricate Connection between Alternative Splicing and Phenotypic Plasticity in Development and Cancer
    Giuseppe Biamonti, Lucia Infantino, Daniela Gaglio, Angela M. Amato · 2019 · Cells
  36. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c‐Myc axis
    Jian‐Yu Yang, Yan‐Miao Huo, Minwei Yang, Yang Shen, Dejun Liu, Xueliang Fu, Ling‐Ye Tao, Ruizhe He, Jun‐Feng Zhang, Rong Hua et al. · 2021 · Molecular Oncology
  37. Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
    Shinsuke Araki, Momoko Ohori, Masato Yugami · 2023 · Frontiers in Oncology
  38. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer
    Nidhi Jyotsana, Michael Heuser · 2017 · Expert Opinion on Therapeutic Targets
  39. Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
    Alex Aleshin, Peter L. Greenberg · 2018 · Blood Advances
  40. Human PRPF40B regulates hundreds of alternative splicing targets and represses a hypoxia expression signature
    Paolo Alberto Lorenzini, Resilind Su Ern Chew, Cheryl Weiqi Tan, Jing Yen Yong, Fan Zhang, Jie Zheng, Xavier Roca · 2019 · RNA
  41. Characterizing the interplay between gene nucleotide composition bias and splicing
    Sébastien Lemaire, Nicolas Fontrodona, Jean-Baptiste Claude, Hélène Polvèche, Fabien Aubé, Laurent Modolo, Cyril F. Bourgeois, Franck Mortreux, Didier Auboeuf · 2019 · Genome biology
  42. Mutations of RNA splicing factors in hematological malignancies
    Girish C. Shukla, Jagjit Singh · 2017 · Cancer Letters
  43. Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences
    So Masaki, Shun Ikeda, Asuka Hata, Yusuke Shiozawa, Ayana Kon, Seishi Ogawa, Kenji Suzuki, Fumihiko Hakuno, Shin‐Ichiro Takahashi, Naoyuki Kataoka · 2019 · Frontiers in Genetics
  44. Targeting Splicing Factor SRSF6 for Cancer Therapy
    Wenting She, Jun Shao, Rong Jia · 2021 · Frontiers in Cell and Developmental Biology
  45. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome
    Nagisa Hasegawa, Motohiko Oshima, Goro Sashida, Hirotaka Matsui, Shuhei Koide, Atsunori Saraya, Changshan Wang, Tomoya Muto, Kiyoko Takane, Atsushi Kaneda et al. · 2016 · Leukemia
  46. Treatment of myelodysplastic syndrome in the era of next‐generation sequencing
    Magnus Tobiasson, Astrid Olsnes Kittang · 2019 · Journal of Internal Medicine
  47. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
    Ella R. Thompson, Tamia Nguyen, Yamuna Kankanige, Paul Sung-Hao Yeh, Michael Ingbritsen, Michelle McBean, Timothy J. Semple, Gisela Mir Arnau, Kate Burbury, Nora Lee et al. · 2020 · Haematologica
  48. A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies
    Xiaolei Liu, Sudhish A. Devadiga, Robert F. Stanley, Ryan M. Morrow, Kevin A. Janssen, Mathieu Quesnel-Vallières, Oz Pomp, Adam A. Moverley, Chenchen Li, Nicolas Skuli et al. · 2024 · Journal of Clinical Investigation
  49. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome
    Mizuho Shirahata‐Adachi, Chisako Iriyama, Akihiro Tomita, Yasuhíro Suzuki, Kazuyuki Shimada, Hitoshi Kiyoi · 2017 · Leukemia Research
  50. SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
    Amandeep Singh Aujla, Katherine J. Linder, Chaitanya Iragavarapu, Michael Karass, Delong Liu · 2018 · Biomarker Research
  51. Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
    Laura Palomo, Pamela Acha, Francesc Gessé Solé · 2021 · Cancers
  52. Genetics of Myelodysplastic Syndromes
    Caner Saygin, Lucy A. Godley · 2021 · Cancers
  53. Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation
    Juliane Grimm, Madlen Jentzsch, Marius Bill, Donata Backhaus, Dominic Brauer, Johannes Küpper, Julia C. Schulz, Georg‐Nikolaus Franke, Vladan Vučinić, Dietger W. Niederwieser et al. · 2021 · American Journal of Hematology
  54. Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations
    Amanda L. Lance, Lawrence J. Druhan, C. Greer Vestal, Nury Steuerwald, Alicia Hamilton, Mathew Smith, Andrea E. Price, Elise Tjaden, Andee N. Fox, Belinda Rene Avalos · 2019 · Leukemia
  55. Myelodysplastic syndrome patient-derived xenografts: from no options to many
    Christophé Côme, Alexander Balhuizen, Dominique A. Bonnet, Bo Torben Porse · 2020 · Haematologica
  56. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer
    Jian Han, Ömer An, Xi Ren, Yangyang Song, Sze Jing Tang, Haoqing Shen, Xinyu Ke, Vanessa Hui En Ng, Daryl Jin Tai Tay, Hui Qing Tan et al. · 2022 · Nature Communications
  57. Molecular Pathogenesis of Myeloproliferative Neoplasms
    Benjamin Rolles, Ann Mullally · 2022 · Current Hematologic Malignancy Reports
  58. The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia
    Jing Chun Yang, Dong‐ming Yao, Ji‐chun Ma, Lei Yang, Hong Yan Guo, Xiang‐mei Wen, Gao-fei Xiao, Zhen Yu Qian, Jiang Lin, Jun Qian · 2016 · Tumor Biology
  59. Peripheral blood cell‐free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes
    Yasuhíro Suzuki, Akihiro Tomita, Fumika Nakamura, Chisako Iriyama, Mizuho Shirahata‐Adachi, Kazuyuki Shimada, Akimi Akashi, Yuichi Ishikawa, Norio Kaneda, Hitoshi Kiyoi · 2016 · Cancer Science
  60. Post-transcriptional regulation in hematopoiesis: RNA binding proteins take control
    Laura P. M. H. de Rooij, Derek C.H. Chan, Ava Keyvani Chahi, Kristin J. Hope · 2018 · Biochemistry and Cell Biology
  61. Identification of a noncanonical RNA binding domain in the U2 snRNP protein SF3A1
    William Martelly, Bernice Fellows, Kristen Senior, Timothy A. Marlowe, Shalini Sharma · 2019 · RNA
  62. The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer
    Anne-Mette Hartung, Jeffrey J. Swensen, Inaki E. Uriz, Morten Lapin, Karen Kristjansdottir, Ulrika Simone Spangsberg Petersen, Jeanne Mari V. Bang, Bárbara Guerra, Henriette S. Andersen, Steven F. Dobrowolski et al. · 2016 · PLoS Genetics
  63. Alternative Splicing in Tumorigenesis and Cancer Therapy
    Huiping Chen, Jingqun Tang, Juanjuan Xiang · 2025 · Biomolecules
  64. RNA splicing, cell signaling, and response to therapies
    Chérine Abou Fayçal, Sylvie Gazzéri, Béatrice Eymin · 2015 · Current Opinion in Oncology
  65. Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation
    Yongsheng Li, Daniel James McGrail, Juan Xu, Gordon Brent Mills, Nidhi Sahni, S. Stephen Yi · 2018 · Trends in Biochemical Sciences
  66. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
    Vikas Madan, Jia Li, Siqin Zhou, Weoi Woon Teoh, Lin Han, Manja Meggendorfer, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Torsten Haferlach et al. · 2019 · American Journal of Hematology
  67. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
    Juan José Rodríguez‐Sevilla, Vera Ademà, Guillermo Garcia‐Manero, Simona Colla · 2023 · Cell Reports Medicine
  68. Targeting alternative splicing in cancer immunotherapy
    Nan Han, Zhaoqi Liu · 2023 · Frontiers in Cell and Developmental Biology
  69. Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
    Marie Hautin, Clélia Mornet, Aurélie Chauveau, Delphine G. Bernard, Laurent Corcos, Éric Lippert · 2020 · Cancers
  70. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice
    Joe Lee, Anna L. Godfrey, Jyoti Nangalia · 2020 · Blood Reviews
  71. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice
    Sanghyun Peter Kim, Sridhar Nonavinkere Srivatsan, Monique Chavez, Cara Lunn Shirai, Brian S. White, Tanzir Ahmed, Michael O. Alberti, Jin Shao, Ryan M. Nunley, Lynn S. White et al. · 2021 · Cell Reports
  72. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
    Tamanna Zohra Haque, Félix López Cadenas, Blanca Xicoy, Ana Alfonso Piérola, Uwe Platzbecker, Irit Mazza Avivi, Andrew Mark Brunner, Jöerg Chromik, Daniel Morillo, Manish R. Patel et al. · 2023 · Leukemia Research
  73. RNA splicing during terminal erythropoiesis
    John G. Conboy · 2017 · Current Opinion in Hematology
  74. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies
    Satoshi Kaito, Atsushi Iwama · 2020 · International Journal of Molecular Sciences
  75. SF3B1 mutant myelodysplastic syndrome: Recent advances
    Andrea Pellagatti, Jacqueline Boultwood · 2020 · Advances in Biological Regulation
  76. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression
    Stephan Bartels, Julia Vogtmann, Elisa Schipper, Guntram Büsche, Jérôme Schlué, Ulrich Lehmann, Hans Heinrich Kreipe · 2021 · European Journal Of Haematology
  77. U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice
    Brian A. Wadugu, Sridhar Nonavinkere Srivatsan, Amanda D. Heard, Michael O. Alberti, Matthew Ndonwi, Jie Liu, Sarah Grieb, Joseph L. Bradley, Jin Shao, Tanzir Ahmed et al. · 2021 · Journal of Clinical Investigation
  78. Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice
    Jane Jialu Xu, Alistair Morgan Chalk, Meaghan Wall, Wallace Y. Langdon, Monique F. M. A. Smeets, Carl R. Walkley · 2022 · Leukemia
  79. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
    Christophe Willekens, Lucie Laplane, Tracy Dagher, Camélia Benlabiod, Nicolas Papadopoulos, Catherine Lacout, Philippe Rameau, Cyril Catelain, Alexia Alfaro, Valérie Edmond et al. · 2023 · Leukemia
  80. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
    Charlotte K. Brierley, David P. Steensma · 2016 · Current Hematologic Malignancy Reports
  81. Smc3 is required for mouse embryonic and adult hematopoiesis
    Tianjiao Wang, Brandi K. Glover, Gayla Hadwiger, Christopher A. Miller, Orsola di Martino, John Sutton Welch · 2018 · Experimental Hematology
  82. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes
    Peipei Lin, Yingwan Luo, Shuanghong Zhu, Dominic M. Maggio, Haiyang Yang, Chao Hu, Jinghan Wang, Hua Zhang, Yanling Ren, Xinping Zhou et al. · 2018 · Journal of Cancer Research and Clinical Oncology
  83. ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells
    Vikas Madan, Zeya Cao, Weoi Woon Teoh, Pushkar Dakle, Lin Han, Pavithra Shyamsunder, Maya Jeitany, Siqin Zhou, Jia Li, Hazimah Binte Mohd Nordin et al. · 2021 · Haematologica
  84. The Coming of Age of Preclinical Models of MDS
    Wei Liu, Patric Teodorescu, Stephanie Halene, Gabriel Ghiaur · 2022 · Frontiers in Oncology
  85. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment
    Andrea Pellagatti, Jacqueline Boultwood · 2022 · Advances in Biological Regulation
  86. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation
    David Rombaut, Carine Lefèvre, Tony Rached, Sabrina Bondu, Anne Letessier, Raphaël M. Mangione, Batoul Farhat, Auriane Lesieur, Daisy Castillo-Guzman, Ismaël Boussaid et al. · 2024 · Nature Communications
  87. Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors
    Gaurang Trivedi, Daichi Inoue, Cynthia Chen, Lillian E Bitner, Young Rock Chung, Justin Taylor, Mithat Gönen, Jürgen Wess, Omar Ibrahim Abdel-Wahab, Lingbo Zhang · 2019 · Science Translational Medicine
  88. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
    Yanbo Nie, Liang Shao, Hong Zhang, Colin K. He, Hongyu Li, Junyan Zou, Long Chen, Huaiyue Ji, Hao Tan, Yani Lin et al. · 2022 · Experimental Hematology and Oncology
  89. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
    Rachel B. Salit, H. Joachim Deeg · 2017 · Transplantation and Cellular Therapy
  90. Therapeutic approaches to treat human spliceosomal diseases
    Anthony B. DeNicola, Yi Tang · 2019 · Current Opinion in Biotechnology
  91. Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice
    Alexis Vedder, Emily L Miedel, Natalie Ragland, Maria E. Balasis, Christopher T. Letson, Robert W. Engelman, Eric Padron · 2019 · Comparative Medicine
  92. Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
    Chiara Naro, Ambra Antonioni, Vanessa Medici, Cinzia Caggiano, Ariane Jolly, Pierre de la Grange, Pamela Bielli, Maria Paola Paronetto, Claudio Sette · 2024 · Journal of Experimental & Clinical Cancer Research
  93. Down-regulation of EZH2 expression in myelodysplastic syndromes
    Mónica Cabrero, Yue Wei, Hui Yang, Irene Gañán‐Gómez, Zach Bohannan, Simona Colla, Matteo Marchesini, Guillermo Montalban Bravo, Koichi Takahashi, Carlos Bueso-Ramos et al. · 2016 · Leukemia Research
  94. Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations
    Joseph Pangallo, Jean‐Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob Tyler Polaski, Khrystyna North, Omar Ibrahim Abdel-Wahab, Robert K. Bradley · 2020 · Blood
  95. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation
    Jane Jialu Xu, Alistair Morgan Chalk, Iva Nikolić, Kaylene J. Simpson, Monique F. M. A. Smeets, Carl R. Walkley · 2021 · Blood Advances
  96. Dysregulated minor intron splicing in cancer
    Koutarou Nishimura, Hiromi Yamazaki, Weijia Zang, Daichi Inoue · 2022 · Cancer Science
  97. The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia
    H.A. Yu, Junshik Hong, Dong‐Yeop Shin, Chul‐Hwan Lee · 2025 · Leukemia
  98. RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications
    Shanhe Huang, Zonglin Li, Weilong Lin, Ruihui Xie, Hai Huang · 2025 · MedComm
  99. Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
    Xiaolei Ding, Xiaojing Yang, Gangning Liang, Kai Wang · 2016 · Scientific Reports
  100. Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions
    Inderpreet Singh, Abhay Singh · 2023 · Current Oncology Reports